One of the largest scientific events in laser dentistry took place from September 22 to 23 in Thessaloniki, Greece. The sixth European Division Congress of the World Federation for Laser Dentistry (WFLD) offered a comprehensive program of presentations and workshops. Furthermore, attendees had the opportunity to exchange information with colleagues about the development and use of laser technology in dentistry.
The World Federation for Laser Dentistry (WFLD) will celebrate its 30th anniversary in 2018. Today it continues to pursue its objective of promoting the exchange, progression and dissemination of laser applications in the dental sector. Regular international events, such as this year’s WFLD Congress in Greece, bring leading experts in laser dentistry together. Both scientists and practitioners demonstrated in presentations where the current opportunities in the area of dental lasers are and provided information about the latest findings and developments in presentations and workshops.
A comprehensive program with more than 100 presentations
The variety of talks over the two days of the event provided the more than 400 attendees from 35 countries with a range of interesting scientific insights. Not only basic knowledge about the subject of laser dentistry was presented here, attention was also targeted on the areas of application such as endodontics, implantology, periodontology and orthodontics. Dentsply Sirona was present at the industry exhibition as the market leader in the dental sector and Gold sponsor of the event. In cooperation with Dr. Joanna Kamma, Dentsply Sirona held a workshop about the application of the SiroLaser Blue in clinical practice.
Dr. Joanna Kamma was one of the experts in attendance and she shared her scientific experiences with the SiroLaser Blue in the form of a workshop. This workshop gave participants a general overview of the areas of application of the SiroLaser Blue with its three wavelengths: the new, blue wavelength (445 nm) used especially in surgery, the red wavelength (660 nm) for applications in the area of photobiomodulation and the infra-red wavelength (970 nm) for bacterial reduction in endodontics and periodontology.
“For the surgical management of the soft tissues, the 445 nm wavelength, due to its properties, has a very good cutting effect with high coagulation and minimal bleeding, minimal thermal tissue damage (heat in the surrounding tissues) and, in addition, a very good wound healing”, explained Dr. Joanna Kamma the advantages of the 445 nm wavelength in the SiroLaser Blue.
Even though the SiroLaser Blue does not yet have approval for the application of the blue wavelength for periodontal bacteria reduction, Dr. Kamma reported about its application based on the existing literature and on the preliminary results of her own clinical studies: “The 445 nm blue light seems to be a very promising adjunct in the non- surgical treatment of chronic periodontitis.”
ABOUT DENTSPLY SIRONA
Dentsply Sirona is the world’s largest manufacturer of professional dental products and technologies, with a 130-year history of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world class brands. As The Dental Solutions Company, Dentsply Sirona’s products provide innovative, high-quality and effective solutions to advance patient care and deliver better, safer and faster dentistry. Dentsply Sirona’s global headquarters is located in York, Pennsylvania, and the international headquarters is based in Salzburg, Austria. The company’s shares are listed in the United States on NASDAQ under the symbol XRAY. Visitt www.dentsplysirona.com for more information about Dentsply Sirona and its products.
DISCLAIMER
This information and any attachment thereto contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance. These forward-looking statements reflect views and assumptions regarding expectations and projections about future events and are based on currently available information or information available on the date of any document incorporated by reference. You can generally identify these forward-looking statements by the use of words such as “may,” “could,” “estimate,” “will,” “believe,” “anticipate,” “think,” “intend,” “expect,” “project,” “plan,” “target,” “forecast”, and similar words and expressions. However, these words are not the exclusive means of identifying such statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and may include statements relating to future revenues, expenses, margins, profitability, net income/(loss), earnings per share and other measures of results of operations and the prospects of future growth of our business. These forward-looking statements are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. For a discussion of such risks, uncertainties and other matters that could cause actual results to differ materially, including risks relating to, among other factors, the market for dental products and services, pricing, future sales volume of the Company’s products, the possibility of changing economic, market and competitive conditions, dependence on products, dependence on key personnel, technological developments, intense competition, market uncertainties, dependence on distributors, ability to manage growth, dependence on key suppliers, dependence on key members of management, government regulation, our ability to integrate the businesses of Dentsply Sirona, acquisitions and affiliations, readers are urged to carefully review and consider various disclosures made by the Company and Dentsply Sirona in their public filings, including in their Annual Reports on Form 10-K and in their reports on Forms 10-Q and 8-K filed with the Securities and Exchange Commission.
Readers are cautioned not to place undue reliance on such statements, which speak only as of the date hereof. Except as required by law, the Company does not assume any obligation to update any forward-looking statements contained in this document or the attachments to reflect new information or future events or developments after the date any such statement is made.
